I've spent 20+ years at the intersection of life sciences, technology, and strategy—leading research teams at NIH, serving as a science diplomat with the State Department, advising Fortune 500 clients at Deloitte and Scimitar, designing Venture Capital and Venture Studios or advising PE with Brinton Bio, and scaling operations at Ginkgo Bioworks.

I started Brinton Bio because I kept seeing the same pattern: brilliant science held back by operational complexity. Leaders drowning in decisions. AI initiatives that never leave the pilot phase. Due diligence that misses the real risks.

I help cut through that complexity. Not with frameworks and slide decks, but with hands-on work that delivers measurable results.

Brinton Bio was created to apply this experience in a focused, execution-oriented way. The firm works with life sciences leaders and capital partners who need decision clarity fast, proof of value in high-leverage workflows, and a credible path to scale—without long, open-ended transformation programs.

Engagements are intentionally scoped, diligence-ready, and designed to leave behind durable operating assets that stand up to scrutiny, turnover, and exit.

My work is global. My clients span from Japan to California to Boston to Europe.